CME
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
February 05, 2024
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted th
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!